Biotech Co.* |
Pharma Co. |
Type/Product Area |
Terms/Details (Date) |
Generex |
Leosons General Trading Co. in 15 Middle Eastern countries, including Saudi Arabia and the United Arab Emirates |
Agreement for Leosons to commercialize Orallyn |
Generex received an up-front license fee (4/23) |
Javelin |
Baxter Healthcare Corp. |
Commercial supply agreement to provide additional manufacturing capacity for Javelin's injectable diclofenac, Dyloject |
During the three-year, renewable term agreement, Baxter will serve as a secondary manufacturer pending regulatory approval (5/22) |
MultiCell |
Lundbeck Pharmaceuticals Italy SpA (Italy) |
Long-term agreement for Lundbeck to supply one of the active components of MCT-125 |
MCT-125 is MultiCell's Phase IIb drug for chronic fatigue in multiple sclerosis patients (4/9) |
MultiCell |
Merck KGaA & Co. |
Agreement to formulate and supply one of the active components of MCT-125, Multicell's Phase IIb drug for chronic fatigue in patients with multiple sclerosis |
Financial details were not disclosed (4/18) |
Salix |
Dr. Falk Pharma GmbH (Germany) |
Exclusive rights agreement to market Diacol 1500 mg tablets in 28 territories in Europe |
Diacol is used in bowel-cleansing applications; Salix may receive up to $4M in milestone payments, as well as royalty payments on sales (4/17) |
Samaritan |
Shire Human Genetic Therapies AB |
Exclusive marketing and distribution agreement to launch and sell Replagal for Fabry's disease in Greece and Cyprus |
Terms of the deal were not disclosed (5/22) |
Sciele Pharma |
LifeCycle |
Exclusive license agreement to market fenofibrate in the U.S., Canada and Mexico in 120-mg and 40- g strengths |
LifeCycle will receive a $5M up-front payment, milestone payments of up to $12M upon FDA approval, as well as tiered mid- teen to high-teen royalty payments; Sciele also entered a collaboration to use Life-Cycle's MeltDose technology and Life- Cycle is entitled to R&D reimbursement, development milestones and mid-single-digit royalties (5/1) |
Vasogen Inc. |
Grupo Ferrer Internacional SA (Spain) |
Collaboration to commercialize Vasogen's Celacade technology in chronic heart failure in the European Union and in certain Latin American countries |
Vasogen will receive 45% of Celacade revenues generated by Ferrer for five years after the first commercial sale on a country-specific basis, and will receive 42% of revenues thereafter; Vasogen also will receive milestone payments (4/18) |
VASTox plc |
Undisclosed |
Commercial collaboration involving VASTox's subsidiary Dextra Laboratories, which specializes in carbohydrate drug discovery and development |
Work will focus on a late-stage product due to launch in 2010 (5/16) |
Vivus Inc. (VVUS) |
KV Pharmaceutical Co. |
Agreement for KV to manufacture, sell and market the menopause drug EvaMist |
Deal is worth $180M in cash to Vivus, which receives $10M up front, $140M upon FDA approval of EvaMist, expected for July, $10M once sales reach $100M in a market year, and $20M once sales reach $200M (3/30) |
| Notes: | |||
| # The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||
